Price Alert

Apellis Pharmaceuticals I... (APLS)

NASDAQ: APLS · Real-Time Price · USD

25.40

-0.64 (-2.46%)

At close: Sep 11, 2025, 3:59 PM

25.40

0.00%

Pre-market: Sep 12, 2025, 07:00 AM EDT

Apellis Pharmaceuticals Statistics

Share Statistics

Apellis Pharmaceuticals has 126.29M shares outstanding. The number of shares has increased by 3.22% in one year.

Shares Outstanding	126.29M
Shares Change (YoY)	3.22%
Shares Change (QoQ)	0.13%
Owned by Institutions (%)	99.99%
Shares Floating	104.28M
Failed to Deliver (FTD) Shares	18
FTD / Avg. Volume	n/a

Short Selling Information

The latest short interest is 20.27M, so 16.05% of the outstanding shares have been sold short.

Short Interest	20.27M
Short % of Shares Out	16.05%
Short % of Float	21.14%
Short Ratio (days to cover)	6.96

Valuation Ratios

The PE ratio is -19.98 and the forward PE ratio is -29.26. Apellis Pharmaceuticals's PEG ratio is 0.31.

PE Ratio	-19.98
Forward PE	-29.26
PS Ratio	5.06
Forward PS	3.6
PB Ratio	17.3
P/FCF Ratio	-44.79
PEG Ratio	0.31

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Apellis Pharmaceuticals.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.25, with a Debt / Equity ratio of 2.06.

Current Ratio	4.25
Quick Ratio	3.81
Debt / Equity	2.06
Debt / EBITDA	-3.04
Debt / FCF	-5.32
Interest Coverage	-4.08

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$1.11M
Profits Per Employee	$-280.68K
Employee Count	705
Asset Turnover	0.88
Inventory Turnover	1.45

Taxes

Income Tax	1.16M
Effective Tax Rate	-0.59%

Stock Price Statistics

The stock price has increased by -30.94% in the last 52 weeks. The beta is 0.72, so Apellis Pharmaceuticals's price volatility has been higher than the market average.

Beta	0.72
52-Week Price Change	-30.94%
50-Day Moving Average	23.46
200-Day Moving Average	24.46
Relative Strength Index (RSI)	45.71
Average Volume (20 Days)	2,319,817

Income Statement

In the last 12 months, Apellis Pharmaceuticals had revenue of 781.37M and earned -197.88M in profits. Earnings per share was -1.6.

Revenue	781.37M
Gross Profit	663.64M
Operating Income	-164.98M
Net Income	-197.88M
EBITDA	-154.53M
EBIT	-156.32M
Earnings Per Share (EPS)	-1.6

Full Income Statement

Balance Sheet

The company has 411.29M in cash and 469.78M in debt, giving a net cash position of -58.49M.

Cash & Cash Equivalents	411.29M
Total Debt	469.78M
Net Cash	-58.49M
Retained Earnings	-3.04B
Total Assets	821.39M
Working Capital	554.95M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -87.87M and capital expenditures -403K, giving a free cash flow of -88.27M.

Operating Cash Flow	-87.87M
Capital Expenditures	-403K
Free Cash Flow	-88.27M
FCF Per Share	-0.71

Full Cash Flow Statement

Margins

Gross margin is 84.93%, with operating and profit margins of -21.11% and -25.32%.

Gross Margin	84.93%
Operating Margin	-21.11%
Pretax Margin	-25.18%
Profit Margin	-25.32%
EBITDA Margin	-19.78%
EBIT Margin	-21.11%
FCF Margin	-11.3%

Dividends & Yields

APLS does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for APLS is $32, which is 26% higher than the current price. The consensus rating is "Hold".

Price Target	$32
Price Target Difference	26%
Analyst Consensus	Hold
Analyst Count	18

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	-1.19
Piotroski F-Score	5